Year-end Sale % OFF 
Abstract
Metastatic colorectal cancer (mCRC) remains the third leading cause of cancer-related deaths worldwide. Wild-type (WT) K-RAS status is a major determinant for the efficacy of anti-EGFR therapy; however, as many as 40-60% patients (pts) even with this genetic background do not benefit from these regimens. While circulating cell-free miRNAs (cf-miRNAs) have emerged as an important class of cancer biomarkers, reent data suggests that miRNAs within the tumor-derived exosomal cargo (exo-miRNAs) might offer higher cancer specificity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
